U.S. President Donald Trump has issued an executive order on Thursday that could potentially reclassify marijuana to a less hazardous category, paving the way for expanded medical research. This move marks a significant departure from current federal drug policy, aligning more closely with the actions taken by numerous states.
The proposed reclassification would shift marijuana from its current designation as a Schedule I substance, alongside heroin and LSD, to a Schedule III classification, similar to ketamine and certain anabolic steroids. While this change would not legalize recreational marijuana nationwide, it could lead to alterations in regulatory approaches and potentially alleviate the substantial tax burden on the cannabis industry.
President Trump cited overwhelming public support for the initiative, emphasizing the potential benefits for patients in need. Notably, the Justice Department under Trump’s predecessor, Joe Biden, also suggested reclassifying marijuana to a Schedule III substance.
Despite some opposition within his party, Trump’s order is expected to expedite the reclassification process currently under review by the Drug Enforcement Administration (DEA). The timeline for implementation remains unclear.
While several states have legalized marijuana for recreational or medical use, federal laws maintain stricter regulations, leaving individuals vulnerable to federal prosecution. Recent polling data from Gallup indicates a growing acceptance of marijuana legalization among Americans.
Additionally, Trump’s executive order includes provisions for enhanced research and access to CBD, a hemp-derived product gaining popularity. A proposed Medicare program would provide eligible older adults with access to legal CBD products at no cost with a doctor’s recommendation.
A group of over 20 Republican senators, including staunch Trump supporters, expressed opposition to the reclassification, citing concerns about the drug’s safety and potential implications. They argued that maintaining marijuana as a Schedule I drug aligns with efforts to uphold public health and safety.
While Trump has not committed to decriminalizing marijuana, his administration has prioritized combating other drugs, particularly fentanyl. Executive actions targeting fentanyl and international drug trafficking have been prominent features of his second term in office.
In conclusion, Trump’s executive order on marijuana reclassification signifies a significant step towards revising federal drug policies, with potential implications for medical research and industry regulations.